Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
140 participants
OBSERVATIONAL
2024-01-01
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD).
2. To detect hepatic risk in subclinical and clinical hypothyroidism .
3. To detect early liver disorders in thyroid disorders using fibroscan .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease
NCT06739330
Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes
NCT06456970
Thyroid Function in Liver Cirrhosis: Is it Affected?
NCT05250401
NAFLD in Patient of Hypothyroidism
NCT05813301
Glucose Disposal Rate as a Metric for Detection of Metabolic Associated Fatty Liver
NCT06923215
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
considering the increasing incidence of NALAD/NASH, especially in developed and developing countries, it is anticipated that cirrhosis due to these conditions may exceed other causes of cirrhosis in a near future..
Thyroid gland is involved in energy homeostasis, lipid and carbohydrate metabolism, regulation of body weight and adipogenesis.
In a clinical setting, subclinical hypothyroidism has been associated with metabolic syndrome, cardiovascular mortality and disturbance of lipid metabolism.
The prevalence of hypothyroidism was reported to 16.8% among patients with NAFLD/NASH.
In recent years, growing body of evidence has led to speculation on the association between NAFLD/NASH and thyroid dysfunction.
Therefore, understanding the pathophysiology, risk factors and new treatment options of NAFLD/NASH should be among the priorities in the field of hepatology
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fibroscan
Scan the liver for metabolic fatty changes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Medications associated with weight gain .
3. Patients who have diabetes mellitus.
4. patients who already have liver disease eg; chronic viral hepatitis, liver cirrhosis.
5. Patients on antistatin.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tasneem Mohammed Ali
Principal investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Hanan Mahmoud, Prof dr
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04-2023-200396
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.